PROGRAM AT A GLANCE
Click on each day to access the program. Purchase your ticket online with registration.
LEGEND: PUBLIC HEALTH | BASIC SCIENCE | CLINICAL SCIENCE
* program is subject to change without notice
Thursday, June 14 2018
| TIME | SESSION TITLE | SPEAKER | PRESENTATION TITLE |
|---|---|---|---|
| 2.00pm-3.45pm | Plenary 1 - WHO Elimination Targets | Gottfried Hirnshchall | Elmination targets: Rationale and WHO's role in helping countries get there |
| David Thomas | What tools are needed to generate the evidence - measuring success | ||
| Gregory Dore | National elimination in a focused epidemic: Australia | ||
| Manal El-Sayed | National elimination in a generalized epidemic: Egypt | ||
| 3.45pm-4.15pm | Afternoon Break | ||
| 4.15pm-6.00pm | HCV Virology | Thomas Baumert | HCV infection and entry |
| Jane McKeating | Physiological regulation of HCV Replication | ||
| Ralf Bartenschlager | HCV virion production and assembly | ||
| Oral Presentation | |||
| Oral Presentation | |||
| 4.15pm-6.00pm | New Biomarkers & Endpoints in HBV | Henry Chan | The value of HBsAg quantification in the natural history and treatment of HBV |
| Jean Michel Pawlotsky | Choosing the right endpoint for HBV treatment | ||
| Harry Janssen | New Biomarkers for HBV infection | ||
| 4.15pm-6.00pm | HEV Pathogenesis & Treatment | Shiv Sarin | HEV and emerging worldwide pathogen? |
| Heiner Wedemeyer | Treatment of HEV infection | ||
| HEV in immunocompromised patients | |||
| Oral Presentation | |||
| Oral Presentation | |||
| 4.15pm-6.00pm | ASLD-ALEH-CASL Pan-American Session | The Pan American Symposium: Viral Hepatitis Among Indigenous Populations In The Americas | |
| 6.00pm-7.30pm | Welcome Reception |
Friday, June 15 2018
| TIME | SESSION TITLE | SPEAKER | PRESENTATION TITLE |
|---|---|---|---|
| 08.30am-10.00am | Plenary 2 - Immune Regulation in Viral Hepatitis | Andrea Cox | Successful Immunity to a Hypervariable virus - Goals of a HCV Vaccine |
| Barbara Rehermann | Regulation of immunity in the era of succesful HCV therapy | ||
| Carlo Ferrari | Powering antiviral T cell function in chronic viral infection | ||
| 10.00am-10.30am | Morning Break | ||
| 10.30am-12.15pm | HCV Immunology & Vaccines | Georg Lauer | Systems biology approaches to understanding T cell immunity in HCV |
| Robert Thimme | Immunity to HCV after spontaneous resolution vs. DAA-mediated clearance of chronic HCV infection | ||
| Michael Houghton | Progress towards a prohylactic HCV vaccine | ||
| Oral Presentation | |||
| Oral Presentation | |||
| 10.30am-12.15pm | HDV Pathogenesis & Treatment | New developments in testing for HDV infection | |
| Heiner Wedemeyer | Current treatments for HDV infection | ||
| Theo Heller | New treatments for HDV | ||
| Oral Presentation | |||
| Oral Presentation | |||
| 10.30am-12.15pm | Elimination Strategies: Microelimination vs National Elimination | Mark Thursz | Micro-elimination: Addressing one population at a time - an attractive approach |
| Sharon Hutchinson | Micro-elmination - not the best approach - national and global strategies are preferred | ||
| Jorge Mera | Cherokee Nation Elimination Project | ||
| Oral Presentation | |||
| Oral Presentation | |||
| 10.30am-12.10pm | HCC Symposium Session 1 - General Session | Global epidemiology of HCC in the 21st Century: Changing etiology of liver disease | |
| Thomas Baumert | Pathogenesis of HCC: Genetic and epigenetic factors | ||
| Morris Sherman | HCC surveillance: How, When and What to do with a positive result | ||
| David Kaplan | Strategies to improve Healthcare delivery for HCC: A Multidisciplinary approach | ||
| 12.15pm-2.00pm | Break / Industry Symposia | ||
| 2.00pm-3.45pm | Fibrosis Biomarkers & Treatment | Keyur Patel | Non-invasive assessment of Fibrosis |
| Scott Friedman | Pipeline of anti-Fibrotic Treatments | ||
| Zack Goodman | Regression of fibrosis/cirrhosis with antiviral therapy | ||
| Oral Presentation | |||
| Oral Presentation | |||
| 2.00pm-3.45pm | HBV Preclinical Therapy Targets | John Tavis | Preclinical viral and host targets for HBV therapy (not cccDNA) |
| Christoph Seeger | Emerging strategies to target HBV cccDNA | ||
| Entry inhibition as a potential curative Regimen for chronic Hepatitis Delta: Implications for future HBV Therapies | |||
| Oral Presentation | |||
| Oral Presentation | |||
| 2.00pm-3.45pm | P.O.C. & Testing Developments | Jean Michel Pawlotsky | Challenges & progress with POC and new diagnostics for HBV & HCV |
| Using the new tests in difficult-to-reach populations | |||
| Rolling out new tests in low and middle income countries - 7 country project | |||
| 2.00pm-3.40pm | HCC Symposium Session 2 - Hepatitis B and HCC | Massimo Levrero | Oncogenesis of HBV-related HCC – virus vs. inflammation |
| Lewis Roberts | Epidemiology of HBV-related HCC – continental perspectives | ||
| George Papatheordorides | Assessing HCC risk in Hepatitis B: How to use different scoring systems | ||
| Ray Kim | Development of HCC in patients with suppressed viral replication: Changes in risk over time | ||
| 3.45pm-4.15pm | Afternoon Break | ||
| 4.15pm-6.00pm | HBV Emerging Therapies | Henry Chan | New antivirals for HBV treatment – early clinical results |
| Ulrike Protzer | Immunological targets: progress and setbacks | ||
| Seng Gee Lim | Is combination or personalized therapy need for success | ||
| Oral Presentation | |||
| Oral Presentation | |||
| 4.15pm-6.00pm | HAV/HDV/HEV Virology | Camille Sureau | Intracellular interplay between HDV and HBV and the impact on viral replication |
| Eui-Cheol Shin | HAV infection, replication and susceptibility to immune control | ||
| Jacques Izopet | Diversity and replication of HEV | ||
| Oral Presentation | |||
| Oral Presentation | |||
| 4.15pm-6.00pm | Economics of HBV & HCV Therapy | Andrew Hill | How low will the prices go? |
| Beyond the drug prices: The economics of addressing viral hepatitis | |||
| Giten Khwairakpam | Overcoming IP, pricing and other barriers to access | ||
| Oral Presentation | |||
| Oral Presentation | |||
| 4.15pm-6.00pm | HCC Symposium Session 3 - Hepatitis C and HCC | Norah Terrault | Assessing HCC risk: who should undergo surveillance (this would include post SVR) |
| Greg Dore | Does the presence of HCC alter the response to HCV treatment | ||
| Antonio Craxi | Recurrence of HCC after Therapy for HCV: Fact or Fiction | ||
| Xavier Forns | Liver transplantation for HCC in hepatitis C: What are the issues |
Saturday, June 16 2018
| TIME | SESSION TITLE | SPEAKER | PRESENTATION TITLE |
|---|---|---|---|
| 08.00am-9.30am | Plenary 3 - The Future of HBV Cure | Geoff Dusheiko | Current treatments and definition of cure |
| Fabien Zoulim | The biological basis of functional cure | ||
| Anna Lok | Clinical challenges of evaluating new therapies | ||
| 9.30am-10.00am | ISVHLD Global Hepatitis Award | Dr. Raymond Schinazi | Conquering One Virus at a Time: From HIV to HCV to HBV |
| 10.00am-10.30am | Morning Break | ||
| 10.30am-12.15pm | HBV Virology | Patrick Kennedy | HBV DNA integration and its impact on the natural history of disease |
| Massimo Levrero | Maintenance and activity of HBV cccDNA | ||
| WenHui Li | Defining the steps of HBV entry from patients to cell culture | ||
| Oral Presentation | |||
| Oral Presentation | |||
| 10.30am-12.15pm | Liver Inflammation & Fibrogenesis | Yujin Hoshida | Mechanisms of carcinogenesis in the cirrhotic liver |
| Ariel Feldstein | Mechanisms and consequences of hepatocyte cell death during liver disease | ||
| Scott Friedman | Regulation of fibrogenesis by stellate cells in liver disease | ||
| Oral Presentation | |||
| Oral Presentation | |||
| 10.30am-12.15pm | HCV Therapy | Ira Jacobson | Debate: Acute HCV – to treat or wait? |
| Gregory Dore | Debate: Acute HCV – to treat or wait? | ||
| Xavier Forns | When and how to treat decompensated patients with HCV | ||
| Francesco Negro | Treating HCV outside of the liver: management of extrahepatic manifestations | ||
| Oral Presentation | |||
| Oral Presentation | |||
| 10.30am-12.15pm | Co-infections | Natasha Martin | What will it take to eliminate HCV/HIV co-infection? |
| Marina Klein | Progress towards HCV/HIV elimination | ||
| Raymundo Parana | HDV: Epidemiology and control strategies | ||
| Oral Presentation | |||
| Oral Presentation | |||
| 12.15pm-2.00pm | Break / Industry Symposia | ||
| 2.00pm-3.45pm | NASH Treatment & Endpoints | Ariel Feldstein | Pathogenesis of NAFLD |
| Rohit Loomba | Current assessment and management of NASH | ||
| NASH Trial Endpoints and Emerging therapies | |||
| Oral Presentation | |||
| Oral Presentation | |||
| 2.00pm-3.45pm | HBV Immunology | Adam Gehring | Monocyte and DC function in chronic HBV and their role in immunomodulatory therapy |
| Antonio Bertoletti | HBV-specific T cell immunity vs. virological control in chronic HBV infection | ||
| Markus Cornberg | Immunological response to stopping Nucleoside Analogues in Chronic HBV | ||
| Oral Presentation | |||
| Oral Presentation | |||
| 2.00pm-3.45pm | Long-term Outcomes After HCV SVR | Adriaan Van der Meer | How do we prove HCV SVR improves HCC, liver failure and mortality? |
| Michael Fried | Extrahepatic benefits of SVR in HCV infection | ||
| Graham Foster | Will liver transplant disappear for HCV infection? | ||
| Oral Presentation | |||
| Oral Presentation | |||
| 2.00pm-3.45pm | Linkage to Care in Viral Hepatitis | Mel Krajden | National screening approaches - not one size fits all |
| Engaging the hard-to-reach - is there evidence on what is working? | |||
| Maud Lemoine | Linkage to care in low-middle income countries - strategies & data | ||
| 3.45pm-4.15pm | Afternoon Break | ||
| 4.15pm-6.00pm | The Global Burden of Viral Hepatitis | Homie Razavi | Global cascade of care for HBV and HCV |
| The burden and the gaps in Asia | |||
| John Ward | The burden and gaps in the Americas | ||
| Olufunmilayo Lesi | The burden and gaps in Africa | ||
| Oral Presentation | |||
| Oral Presentation | |||
| 4.15pm-6.00pm | Viral Hepatitis & Transplant | Rajender Reddy | Use of HCV infected donors in transplantation? |
| Gonzalo Sapisoschin | Pushing the envelop: extended criteria for transplantation in HCC | ||
| Marina Berenguer | Management of HBV after organ transplantation | ||
| Barjesh Chander Sharma | Acute on chronic liver failure in viral hepatitis | ||
| Oral Presentation | |||
| 4.15pm-6.00pm | Clinical Management of HBV | Jin Lin Hou | Long-term benefits provided by current generation of nucleoside analogues |
| Jordan Feld | How to handle antiviral treatment in immuno-suppressed patients | ||
| Carla Coffin | Management of HBV in pregnancy | ||
| Oral Presentation | |||
| Oral Presentation | |||
| 4.15pm-6.00pm | Control Strategies in Special Populations | Christina Greenaway | The migrant crisis: A challenge for elimination efforts? |
| Shruthi Mehta | Control strategies in PWID | ||
| TBA | Role of community in the global response | ||
| Oral Presentation | |||
| Oral Presentation | |||
| 7.00pm | Evening Social Event |
Sunday, June 17 2018
| TIME | SESSION TITLE | SPEAKER | PRESENTATION TITLE |
|---|---|---|---|
| 08.30am-10.00am | Plenary 4 - HCV Treatment - Remaining Challenges | Ira Jacobson | Current Treatments for HepC - is there anything left to optimize |
| Mark Sulkowski | Overcoming current challenges in delivery effective therapy | ||
| Michael Manns | Clinical Impact of HCV treatment | ||
| 10.00am-10.30am | Morning Break | ||
| Maura Dandri | Humanized mice for the study of HBV and HDV infection | ||
| Lorne Tyrell | Cell culture infection models to study viral hepatitis | ||
| Massimiliano Paganelli | iPS-derived Hepatocytes for the study of liver disease | ||
| Nick Crispe | Culture and maintenance of primary liver Tissue | ||
| Oral Presentation | |||
| 10.30am-12.15pm | Starting & Stopping HBV treatment | Scott Fung | When to start or restart treatment for HBV |
| George Papatheodorides | Debate: Can we stop nucleoside analogues before HBsAg loss? | ||
| Pietro Lampertico | Debate: Can we stop nucleoside analogues before HBsAg loss? | ||
| Adrian DiBisceglie | Should we treat patients with HBeAg+ infection (immune tolerant)? | ||
| Oral Presentation | |||
| Oral Presentation | |||
| 10.30am-12.15pm | TasP and Other Prevention Strategies | Julio Montaner | Treatment as Prevention: Lessons from HIV |
| Margaret Hellard | Treatment as prevention in practice: The Prison experience | ||
| Mark Tyndall | Harm Reduction in the context of the North American opiate epidemic | ||
| Oral Presentation | |||
| Oral Presentation | |||
| 10.30am-12.15pm | Vaccination in HAV/HEV/HBV | Mark Thursz | HBV vaccination - Is the birth dose the Achilles heel to success? |
| Homie Razavi | Should changing epidemiology change HAV vaccination policy? | ||
| Eyasu Teshale | HEV vaccination strategies - outbreak control vs routine vaccination | ||
| Oral Presentation | |||
| Oral Presentation |